AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14627850
Drug: High density
RxNorm normalized name: High density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High density porous polyethylene (Medpore) implants
Trial: 27098822
Drug: Colistin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin plus meropenem combination therapy
Trial: 22682898
Drug: Denufosol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denufosol (60 mg via inhalation three times daily)
Trial: 20679620
Drug: Vinblastine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (6 mg/m²) during each chemotherapy course followed by weekly vinblastine for a total of 1 year
Trial: 17880718
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (analgesics as needed)
Trial: 17880718
Drug: Cost effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost effectiveness of corticosteroid injection therapy
Trial: 16141015
Drug: Heliox-driven albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox-driven albuterol therapy
Trial: 7745800
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of 4% lidocaine HCl
Trial: 7745800
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of nicardipine HCl + 5 ml of distilled water
Trial: 7745800
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of verapamil HCl + 5 ml of distilled water
Trial: 7745800
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of diltiazem HCl + 5 ml of distilled water
Trial: 2134114
Drug: Buspirone (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (initial dose 15 mg, mean final dose 22.2 mg)
Trial: 2134114
Drug: Oxazepam (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (initial dose 45 mg, mean final dose 55.8 mg)
Trial: 29890542
Drug: Leucine administration
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine administration (25g) with glucose infusion
Trial: 29890542
Drug: Control (250ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (250ml water with glucose infusion)
Trial: 27259300
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of Tirofiban and Fondaparinux
Trial: 21464426
Drug: Interferon β‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β‐1b 250 μg
Trial: 21464426
Drug: Interferon β‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon β‐1b 500 μg
Trial: 9893539
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 1 mg.kg‐1 (T1)
Trial: 9893539
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 2 mg.kg‐1 (T2)
Trial: 9893539
Drug: Intravenous pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pethidine 1 mg.kg‐1 (PE)
Trial: 29267375
Drug: Standard versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard versus New Antiepileptic Drugs (SANAD) treatment
Trial: 23390177
Drug: Verum stimulation
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum stimulation (Cefaly, STX‐Med., Herstal, Belgium) applied daily for 20 minutes for 3 months
Trial: 22005160
Drug: Rapid initiation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid initiation of quetiapine (up to 800 mg/d by Day 4)
Trial: 22005160
Drug: Conventional initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional initiation of quetiapine (up to 400 mg/d by Day 5)
Trial: 19200399
Drug: Supervised multi-modal
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised multi-modal exercise therapy programme
Trial: 19200399
Drug: Individualised manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised manual therapy programme
Trial: 19200399
Drug: Both exercise
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both exercise therapy and manual therapy
Trial: 15164336
Drug: Egg diet
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg diet (640 mg/d additional dietary cholesterol)
Trial: 15164336
Drug: Placebo diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diet (0 mg/d additional dietary cholesterol)
Trial: 11240880
Drug: Diclofenac 1-2
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 1-2 mg.kg-1
Trial: 11240880
Drug: Acetaminophen 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 22.5 mg.kg-1
Trial: 3682574
Drug: reserpin (0.5‐0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reserpin (0.5‐0.75 mg/day)
Trial: 3682574
Drug: dopegyt (750‐1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dopegyt (750‐1500 mg/day)
Trial: 3682574
Drug: clophelin (0.3‐0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clophelin (0.3‐0.6 mg/day)
Trial: 3682574
Drug: anaprilin (80‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anaprilin (80‐160 mg/day)
Trial: 3682574
Drug: hydrochlorothiazide (25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25‐100 mg/day)
Trial: 28687830
Drug: Cetuximab added
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab added to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions.
Trial: 28687830
Drug: Weekly concurrent
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions without cetuximab.
Trial: 28687830
Drug: Cetuximab added
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab added to concurrent chemoradiation.
Trial: 25385096
Drug: Primaquine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine alone (30 mg base)
Trial: 25385096
Drug: Pyronaridine-artesunate alone
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pyronaridine-artesunate alone (540-180 mg)
Trial: 23266402
Drug: Nebulized Dornase
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Dornase alfa administered twice daily until extubation, death, or transfer
Trial: 23266402
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily until extubation, death, or transfer
Trial: 17000366
Drug: D-dimer greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer greater than 4.1 mmol/L
Trial: 8682466
Drug: Combined locoregional
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined locoregional immuno-chemotherapy (Group B)
Trial: 8682466
Drug: Locoregional chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional chemotherapy (Group A)
Trial: 1868748
Drug: Naftifine gel
RxNorm normalized name: naftifine Topical Gel
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine gel 1 percent applied twice daily for four weeks
Trial: 1868748
Drug: Gel vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel vehicle applied twice daily for four weeks
Trial: 31008751
Drug: Dexmedetomidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.25 µg/kg
Trial: 30985379
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 µg/kg)
Trial: 29724499
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 250 mg TID
Trial: 29724499
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 500 mg TID
Trial: 11139861
Drug: Maternity gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternity gel pads
Trial: 9132351
Drug: Subcutaneous Redon
RxNorm normalized name: Redox-phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous Redon drains
Trial: 3523240
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin given for five days
Trial: 16617220
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention based on cognitive behavioral therapy
Trial: 12716076
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (Ca‐A)
Trial: 12716076
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor (ACE‐I)
Trial: 11066055
Drug: Oral chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chemotherapy with trofosfamide (100 mg/m2) and etoposide (25 mg/m2), daily or for 21-day cycles interrupted by 1-week rests, with concurrent standard fractionated radiation (54 grays).
Trial: 8840284
Drug: Chronic rEPO
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic rEPO therapy
Trial: 8840284
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving rEPO therapy
Trial: 1632179
Drug: Succinylcholine (groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (groups F, G)
Trial: 1632179
Drug: Lidocaine in
RxNorm normalized name: lidocaine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine in combination with atracurium (group D)
Trial: 1632179
Drug: Lidocaine in
RxNorm normalized name: lidocaine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine in combination with succinylcholine (group G)
Trial: 28976210
Drug: Vigna nakashimae
RxNorm normalized name: Vigna radiata extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigna nakashimae extract (1 g thrice daily)
Trial: 28976210
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (control group)
Trial: 24226568
Drug: Clobetasol propionate,
RxNorm normalized name: Clobetasol Propionate, 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol propionate, 0.05% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Trial: 24226568
Drug: Hydrocortisone, 1%
RxNorm normalized name: MD Hydrocortisone, 1% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone, 1% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Trial: 22830016
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg/d and Tretinoin 10 mg/BID for six months
Trial: 22830016
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Pioglitazone and Tretinoin)
Trial: 19128256
Drug: Biatain Ibu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biatain Ibu Nonadhesive (foam dressing with ibuprofen)
Trial: 19128256
Drug: Biatain Non-Adhesive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biatain Non-Adhesive (foam dressing without ibuprofen)
Trial: 16648092
Drug: Reflexology treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatments
Trial: 14665498
Drug: Guaifenesin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaifenesin (400 mg)
Trial: 11035667
Drug: European Commission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European Commission for Steel and Coal questionnaire and spirometry with bronchodilator test
Trial: 8767350
Drug: Isradipine monotherapy
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine monotherapy (n = 32)
Trial: 8767350
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Isradipine + metoprolol/enalapril) (n = 11)
Trial: 8767350
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single administration of isradipine 5 mg for responsiveness testing)
Trial: 1623868
Drug: Prehospital thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital thrombolytic treatment with anistreplase
Trial: 1623868
Drug: In-hospital thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital thrombolytic treatment with anistreplase
Trial: 6435272
Drug: Cefamandole nafate
RxNorm normalized name: Cefamandole Nafate
DrugBank: Cefamandole nafate (DB14725)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefamandole nafate 2 gm administered intravenously preoperatively and 6 hours postoperatively in four doses
Trial: 6435272
Drug: Cefamandole nafate
RxNorm normalized name: Cefamandole Nafate
DrugBank: Cefamandole nafate (DB14725)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefamandole nafate 0.4% solution: 250 ml to irrigate the abdominal wound on opening, 500 ml to irrigate the peritoneal cavity, and 250 ml to irrigate the wound on closing
Trial: 6435272
Drug: Systemic plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic plus topical administrations as in Nos. 1 and 2
Trial: 31568000
Drug: Adjuvant moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant moxibustion therapy with usual care for 12 weeks (24 sessions)
Trial: 31568000
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (acetaminophen on demand and self-directed exercise education)
Trial: 31568000
Drug: Adjuvant moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant moxibustion therapy
Trial: 22146409
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta‐1a three times a week
Trial: 22146409
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta‐1a once a week
Trial: 12003177
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) during structured treatment interruptions (STI) of HAART
Trial: 12003177
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruptions (STI) of HAART
Trial: 24206639
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation treatment (weekly group-based for 12 weeks)
Trial: 19517247
Drug: Memantine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine at a dose of 20 mg/day
Trial: 12469544
Drug: Multicomponent medication
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent medication adherence intervention (behavioral strategies, simplified patient information, social support, cognitive‐behavioral therapy, nursing)
Trial: 12469544
Drug: Multicomponent medication
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent medication adherence intervention
Trial: 9802635
Drug: Oral tetravalent
RxNorm normalized name: rotavirus vacc, live oral tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tetravalent rotavirus vaccine (RV‐TV)
Trial: 8575610
Drug: Fundus III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fundus III oral liquid (10ml/time P.O. t.i.d. for 1 month)
Trial: 2197910
Drug: Inhaled pentamidine
RxNorm normalized name: pentamidine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled pentamidine (8 mg/kg body weight)
Trial: 2197910
Drug: Intravenous pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pentamidine (4 mg/kg body weight)
Trial: 2197910
Drug: Inhaled pentamidine
RxNorm normalized name: pentamidine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled pentamidine
Trial: 92830
Drug: Neutron treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron treatment (full course of 16 Gy)
Trial: 92830
Drug: Neutron treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron treatment (reduced doses of 10 to 14 Gy)
Trial: 28009692
Drug: 10,600 nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,600 nm ablative fractional carbon dioxide (CO2) laser treatment (3 sessions)
Trial: 24382970
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK cell treatment
Trial: 8807183
Drug: PCORA (Patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCORA (Patient Controlled Oral Analgesia)
Trial: 8807183
Drug: CPPT (Customarily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPPT (Customarily Prescribed Pain Therapy)
Trial: 1679661
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine (20 mg)
Trial: 1679661
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (celiprolol and nifedipine)
Trial: 1679661
Drug: Intravenous celiprolol
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous celiprolol (8 mg) during exercise
Trial: 1679661
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine (20 mg) during exercise
Trial: 1679661
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy during exercise
Trial: 30514115
Drug: Group exercises
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group exercises (strength and aerobic exercises) performed twice a week for 24 weeks
Trial: 26905112
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy (5 fluorouracil, adriamycin, and cyclophosphamide) followed by modified radical mastectomy
Trial: 26905112
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after modified radical mastectomy
Trial: 24942155
Drug: Chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chronic low-dose recombinant human follicle-stimulating hormone (r-hFSH) protocol (starting daily dose: 75 IU, dose increase on Day 14)
Trial: 24942155
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human follicle-stimulating hormone (r-hFSH) protocol (starting daily dose: 75 IU, dose increase on Day 7)
Trial: 12039482
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) streptokinase
Trial: 781231
Drug: Aspirin (3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.9 gm/day)
Trial: 26382562
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser adjunct treatment (1.0 W power, pulsed mode, λ 810 nm, energy density 3 J/cm², time 1 min, power density 400 mW/cm², energy 1.5 J, spot diameter 1 mm)
Trial: 25046945
Drug: Chinese Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Compound Shenhuang Ointment (CSO)
Trial: 17026493
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp30)
Trial: 20460999
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (30 ml)
Trial: 20460999
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% (20 ml)
Trial: 20460999
Drug: Ropivacaine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 20 ml (ED(concentration)50/ED(concentration)95)